isoleucinal

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: isoleucinal
• 英文别名: isoleucyle；isoleucine；2-Amino-3-methylpentanal
• 化学式: C₆H₁₃NO
• mdl: MFCD19205748
• 分子量: 115.175
• InChiKey: QCAAXUQRSHUEHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  isoleucinal 以 水 、 乙酸乙酯 为溶剂， 反应 1.0h， 以0.035 g的产率得到2,5-双(1-甲基丙基)吡嗪
  参考文献：
  名称：

  对称双取代吡嗪合成的新方法

  摘要：

  通过α-氨基醛的自缩合，可以通过三步一锅法完成对称的双取代吡嗪的合成。通过用氢化二异丁基铝处理天然α-氨基酸的甲酯可以轻松获得α-氨基醛。

  DOI：

  10.1002/jhet.1748
• 作为产物：
  描述：

  2-Amino-3-methyl-pentanoic acid methyl ester 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 isoleucinal
  参考文献：
  名称：

  对称双取代吡嗪合成的新方法

  摘要：

  通过α-氨基醛的自缩合，可以通过三步一锅法完成对称的双取代吡嗪的合成。通过用氢化二异丁基铝处理天然α-氨基酸的甲酯可以轻松获得α-氨基醛。

  DOI：

  10.1002/jhet.1748

文献信息

• [EN] A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS<br/>[FR] CONJUGUÉ D'UNE TOXINE D'AMANITE AVEC DES LIEURS RAMIFIÉS
  申请人：HANGZHOU DAC BIOTECH CO LTD

  公开号：WO2020155017A1

  公开（公告）日：2020-08-06

  Provided herein is the conjugation of an amanita toxin compound to a cell-binding molecule with branched linkers for having better targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of an amanita molecule to a cell-binding ligand, as well as methods of using the conjugate in targets treatment of cancer, infection and autoimmune disease.

  本文提供了一种将鹅膏菌毒素化合物与具有分支连接物的细胞结合分子结合，以实现更好地针对异常细胞进行治疗。它还涉及将鹅膏菌分子与细胞结合配体结合的分支连接方法，以及在癌症、感染和自身免疫疾病治疗中使用该结合物的方法。
• COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR
  申请人：HUMAN BIOMOLECULAR RESEARCH INSTITUTE

  公开号：US20160038641A1

  公开（公告）日：2016-02-11

  Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, transdifferentiation, and proliferation of animal cells into the osteoblast blast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes.

  描述了由小分子、基质和孤立细胞组成的组合物，包括制备方法，以及动物细胞分化、转分化和增殖成骨母细胞谱系的方法。给细胞施加的或与细胞共培养的成骨材料的示例由独立或首选与基质组合的Formula II、IV和VI化合物代表。受小分子刺激的细胞还与基质结合，与细胞粘合剂或材料载体一起植入到动物体内的部位进行骨修复。预先用Formula II、IV和VI化合物处理的基质也被用于导致细胞迁移到用于治疗目的的基质上。
• Lincomycin derivatives possessing antibacterial activity
  申请人：VICURON PHARMACEUTICALS INC.

  公开号：US20040230046A1

  公开（公告）日：2004-11-18

  Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against bacteria, including gram positive organisms, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

  揭示了新颖的林可霉素衍生物。这些林可霉素衍生物表现出抗菌活性。由于本发明的化合物对细菌，包括革兰氏阳性生物，表现出强大的活性，它们是有用的抗微生物药剂。还公开了这些化合物的合成和使用方法。
• [EN] BIOLOGICALLY ACTIVE COMPOUNDS<br/>[FR] COMPOSES A ACTIVITE BIOLOGIQUE
  申请人：AMURA THERAPEUTICS LTD

  公开号：WO2004007501A1

  公开（公告）日：2004-01-22

  Compounds of general formula (I) wherein: Z = CR3R4, where R3 and R4 are independently chosen from CO-7-alkyl P1 = CR5R6, P2 = O, CR7R8 or NR9, Y = CR10R11-C(O) or CR10R11-C(S) or CR10R11-S(O) or CR10R11-SO2 (X)o=.CR16R17 (W)n = 0, S, C(O), S(O) or S(O)2-or NR18 (V)m = C(O), C(S), S(O), S(O)2, S(O)2NH, OC(O), NHC(O), NHS(O), NHS(O)2, OC(O)NH, C(O)NH or CR19R20, C=N-C(O)-OR19 or C=N-C(O)-NHR19, U = a stable. 5- to 7-membered monocyclic or a stable 8- to 11-membered bicyclic ring which is either saturated or unsaturated, and which includes zero to four heteroatoms and their salts, hydrates, solvates, complexes and prodrugs are inhibitors of cathepsin K and other cysteine protease inhibitors and are useful as therapeutic agents, .for example in osteoporosis, Paget's disease gingival diseases such as gingivitis and periodontitis, hypercalaemia of malignancy, metabolic bone disease, diseases involving matrix or cartilage degradation, in particular osteoarthritis and rheumatoid arthritis and neoplastic diseases. The compounds are also useful for validating therapeutic target compounds.

  通式（I）的化合物中：其中：Z = CR3R4，其中R3和R4分别选择自CO-7-烷基P1 = CR5R6，P2 = O，CR7R8或NR9，Y = CR10R11-C（O）或CR10R11-C（S）或CR10R11-S（O）或CR10R11-SO2（X）o = .CR16R17（W）n = 0，S，C（O），S（O）或S（O）2-或NR18（V）m = C（O），C（S），S（O），S（O）2，S（O）2NH，OC（O），NHC（O），NHS（O），NHS（O）2，OC（O）NH，C（O）NH或CR19R20，C = N-C（O）-OR19或C = N-C（O）-NHR19，U = a stable。5-至7-成员单环或稳定的8-至11-成员双环，其饱和或不饱和，并包括零至四个杂原子及其盐、水合物、溶剂合物、络合物和前药是猫hepsin K和其他半胱氨酸蛋白酶抑制剂的抑制剂，并可用作治疗剂，例如在骨质疏松症、Paget病、牙龈疾病如牙龈炎和牙周炎、恶性高钙血症、代谢性骨病、涉及基质或软骨降解的疾病，特别是骨关节炎和类风湿性关节炎和肿瘤性疾病。这些化合物还可用于验证治疗靶点化合物。
• [EN] SELECTIVE PYY COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS PYY SÉLECTIFS ET LEURS UTILISATIONS
  申请人：NOVO NORDISK AS

  公开号：WO2016124687A1

  公开（公告）日：2016-08-11

  The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 10 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

  该发明涉及PYY化合物，其氨基酸在与hPYY(1-36)的位置30对应的位置上被色氨酸及其衍生物取代，同时在与hPYY(1-36)的位置10对应的位置上附有修饰基团。该发明的化合物是选择性Y2受体激动剂。该发明还涉及包含这种PYY化合物和药用可接受辅料的制药组合物，以及PYY化合物的医药用途。